SCHEDULE: Kala Bio Investor Discloses Share Holdings

Sentiment:

Beneficial Ownership Filing 2 July 2026 5:37 PM

David E. Lazar amends Schedule 13D, reporting beneficial ownership of 719,404 shares, representing 3.9% of Kala Bio, Inc.'s outstanding common stock.

Summary

David E. Lazar has filed an amendment to Schedule 13D concerning his beneficial ownership of Kala Bio, Inc. common stock.
As of the close of business on the filing date, Lazar beneficially owns 719,404 shares.
This ownership represents 3.9% of the company's outstanding common stock, based on 18,589,787 shares outstanding as of June 9, 2026.
The total purchase price for these shares, received upon conversion of Series AA Preferred Stock, was $1,308,007.
Lazar has sole voting power and sole dispositive power for all 719,404 shares.
Transactions in the shares by Lazar during the past sixty days are detailed in Exhibit 1.
As of April 24, 2026, Lazar was no longer the beneficial owner of more than 5% of the outstanding shares.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this filing as neutral to slightly negative due to the disclosure of significant share sales by a major holder, although it provides necessary transparency.

Positives

David E. Lazar maintains a significant stake in Kala Bio, Inc., indicating continued investor interest.
The filing clearly outlines the beneficial ownership and voting/dispositive power, providing transparency to the market.

Negatives

The filing details multiple sales of common stock by David E. Lazar over the past 60 days, totaling a significant number of shares.
Lazar's beneficial ownership has fallen below the 5% threshold at one point, indicating a reduction in his stake relative to the total outstanding shares.

Risks

The ongoing sales of shares by a significant holder could potentially exert downward pressure on the stock price.
The conversion of preferred stock and subsequent sales might suggest a strategy to liquidate holdings rather than long-term investment.

Future Outlook

The filing does not contain explicit forward-looking statements or guidance from the company. It primarily reports on beneficial ownership and past transactions of David E. Lazar.

Industry Context

StockSavvy.ai notes that Schedule 13D filings are crucial for tracking significant ownership changes and potential shifts in control or influence within a company. This filing by David E. Lazar provides insight into a substantial shareholder's activity and current stake in Kala Bio, Inc., a biotechnology company.

Stakeholder Impact

Shareholders: The sales by David E. Lazar may influence market sentiment and potentially impact share price. Transparency in ownership is maintained.
Company Management: The filing provides clarity on a significant shareholder's position, which can be relevant for strategic planning and investor relations.

Next Steps

Monitor future filings by David E. Lazar for any further changes in beneficial ownership.
Observe Kala Bio, Inc.'s stock performance and company announcements for context regarding shareholder activity.

Key Dates

Date	Description
2026-04-24	Date as of which the Reporting Person ceased to be the beneficial owner of more than 5% of the outstanding Shares.
2026-05-04	Date of sale of 7,142 shares of Common Stock.
2026-05-05	Date of sale of 8,000 shares of Common Stock.
2026-05-08	Date of 1-for-50 reverse stock split effected by the Issuer.
2026-05-19	Date of sale of 15,000 shares of Common Stock.
2026-05-20	Date of sale of 22,500 shares of Common Stock.
2026-05-21	Date of sale of 14,287 shares of Common Stock.
2026-05-26	Date of sale of 7,218 shares of Common Stock.
2026-05-27	Date of sale of 995 shares of Common Stock.
2026-06-09	Date as of which 18,589,787 shares were outstanding.
2026-06-12	Date of Form S-3/A filing by the Issuer.
2026-06-29	Date of sale of 30,595 shares of Common Stock.
2026-07-02	Date of signature on the Schedule 13D filing.

Recommendation

hold

Based solely on this Schedule 13D filing, which details ownership and past transactions of a significant investor rather than company performance, a 'hold' recommendation is appropriate. The filing itself does not provide sufficient information to warrant a buy or sell decision, but the disclosed sales activity warrants monitoring.

Keywords

Kala Bio, Schedule 13D, David E. Lazar, Beneficial Ownership, Common Stock, SEC Filing, Shareholder, Investment

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.